JIN-A02, a new 4th generation EGFR TKI selected for the European Thoracic Oncology Platform


Seoul, South Korea, August 11, 2022 /PRNewswire/ — J ORGANIC INTS announced that preclinical data of its new orally administered 4th generation EGFR TKI “JIN-A02” was presented at the IASLC 2022 World Conference on Lung Cancer in Vienna, Austria The 8the August, during the official session “Overcoming resistance to EGFR inhibitors”.


In addition, abstract no. MA07.08 titled “JIN-A02, a Highly Effective 4th Generation EGFR-TKI, Targeting EGFR C797S Mutation in NSCLC” was selected by the editors of the European Thoracic Oncology Platform (ETOP), for inclusion in a slide set of key highlights which will be uploaded on its official website: http://www.etop-eu.org/. Generally, a limited number of abstracts from the hundreds accepted are selected for this honor at each international meeting. And that’s rare for a product at the preclinical stage.

It is also the first time that a Korean company has been selected for inclusion in the European Thoracic Oncology Platform (ETOP) and demonstrates that “JIN-A02” has been widely recognized by the international oncology community as a game-changer and has the potential to be the best-in-class 4th generation EGFR TKI in the treatment of NSCLC with double and triple C797S mutations.

About the European Thoracic Oncology Platform (ETOP)

ETOP is a nonprofit organization that promotes academic clinical research and the exchange of ideas in the field of thoracic oncology and includes more than 50 collaborative groups and institutions worldwide. Europe and beyond. ETOP sponsors and administers a growing number of translational studies and clinical trials serving as a meeting platform for European study groups and institutions engaged in research on thoracic malignancies.


J ORGANIC INTS is a bio-based company specializing in the development of innovative cancer and orphan drugs to achieve the goal of changing lives and improving the health of patients worldwide. J ORGANIC INTS The teams have years of previous experience in multinational pharmaceutical companies and CROs and backgrounds in medical affairs, regulatory affairs, drug discovery and development.

About ‘JIN-A02’

‘JIN-A02’ is an orally administered novel 4e EGFR TKI generation targeting C797S mutations in NSCLC. Although 1st, 2nd, and 3rd generation EGFR TKIs have been used with some success, recurrence occurs in most patients, including 3rd Generation TKIs such as Osimertinib. Currently, there are no approved treatments for patients who have developed EGFR C797S mutations due to the use of 3rd Generation of IGFR TKIs and with the high propensity of these cancers to metastasize to the brain, there is an urgent need to develop an effective drug with high blood-brain barrier permeability. ‘JIN-A02’, a novel oral EGFR TKI, effective against C797S mutations and having high cerebral penetrance, is therefore expected to become the most promising 4th generation IGFR TKI in NSCLC patients with viable treatment options.



Show original content to download multimedia:https://www.prnewswire.com/news-releases/jin-a02-a-novel-4th-generation-egfr-tki-selected-for-the-european-thoracic-oncology-platform–a-first-for -korean-pharma-301604799.html



About Author

Comments are closed.